Dana Pizzuti
CIK 1948238 · Chief Med and Dev Officer · last filed 2025-12-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRNX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6055 LUSK BOULEVARD
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Chief Med and Dev Officer | 66,837 | $84.95 | $5.68M | -$7.11M | 22 | 2025-12-03 |
Recent Filings · Page 2 of 4
40 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-02 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −5,000 | -$154.9K | EDGAR |
| 2025-08-26 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Mixed | — | -$406.2K | EDGAR |
| 2025-08-22 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −30,000 | -$882.0K | EDGAR |
| 2025-08-21 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Sell (S) | −6,492 | -$189.4K | EDGAR |
| 2025-08-20 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −6,492 | -$191.1K | EDGAR |
| 2025-03-21 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Sell (S) | −2,515 | -$86.0K | EDGAR |
| 2025-02-24 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Grant (A) | +43,000 | $0 | EDGAR |
| 2025-02-05 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Mixed | — | -$110.9K | EDGAR |
| 2025-02-03 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −5,000 | -$195.4K | EDGAR |
| 2025-01-07 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Mixed | +2,500 | -$478.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.